AI Article Synopsis
- Peripheral blasts (PB) in myelofibrosis patients are linked to worse outcomes, with PB levels of 4% or higher significantly impacting prognosis.
- A study of 794 chronic-phase myelofibrosis patients treated with ruxolitinib (RUX) found that those with higher PB percentages had poorer responses in spleen size reduction and overall survival compared to those without PB.
- The findings suggest that patients with higher PB levels may benefit from treatment strategies that go beyond standard RUX therapy.
Article Abstract
Background: The presence of peripheral blasts (PB) is a negative prognostic factor in patients with primary and secondary myelofibrosis (MF) and PB ≥4% was associated with a particularly unfavorable prognosis. Ruxolitinib (RUX) is the JAK1/2 inhibitor most used for treatment of MF-related splenomegaly and symptoms. Its role has not been assessed in correlation with PB.
Methods: In 794 chronic-phase MF patients treated with RUX, we evaluated the impact of baseline percentage of PB on response (spleen and symptoms responses) and outcome (RUX discontinuation-free, leukemia-free, and overall survival). Three subgroups were compared: PB-0 (no PB, 61.3%), PB-4 (PB 1%-4%, 33.5%), and PB-9 (PB 5%-9%, 5.2%).
Results: At 3 and 6 months, spleen responses were less frequently achieved by PB-4 (P = .001) and PB-9 (P = .004) compared to PB-0 patients. RUX discontinuation-free, leukemia-free, and overall survival were also worse for PB-4 and PB-9 patients (P = .001, P = .002, and P < .001, respectively).
Conclusions: Personalized approaches beyond RUX monotherapy may be useful in PB-4 and particularly in PB-9 patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325504 | PMC |
| http://dx.doi.org/10.1002/cncr.34216 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!